Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea

Authors
Hee Yeon LeeJi Hyung HongJae Ho ByunHee-Jun KimSun Kyung BaekJin Young KimKi Hyang KimJina YunJung A KimKwonoh ParkHyo Jin LeeJung Lim LeeYoung-Woong WonIl Hwan KimWoo Kyun BaeKyong Hwa ParkDer-Sheng SunSuee LeeMin-Young LeeGuk Jin LeeSook Hee HongYun Hwa JungHo Jung An
Department
Dept. of Internal Medicine (내과학)
Issue Date
2020
Citation
Cancer Research and Treatment, Vol.52(1) : 277-283, 2020
ISSN
2005-9256
Abstract
Purpose: To evaluate clinical characteristics and treatment pattern of ovarian clear cell carcinoma (OCCC) in Korea and the role of adjuvant chemotherapy in early stage Materials and Methods: Medical records of 308 cases of from 21 institutions were reviewed and data including age, performance status, endometriosis, thromboembolism, stage, CA-125, treatment, recurrence, and death were collected. Results: Regarding stage of OCCC, it was stage I in 194 (63.6%), stage II in 34 (11.1%), stage III in 66 (21.6%), and stage IV in 11 (3.6%) patients. All patients underwent surgery. Optimal surgery (residual disease ≤1cm) was achieved in 89.3%. Majority (80.5%) of patients received postoperative chemotherapy. The most common regimen was taxane-platinum combination (96%). Median relapse-free survival (RFS) was 138.5 months for stage I, 33.4 for stage II, 19.3 for stage III, and 9.7 for stage IV. Median overall survival (OS) were not reached, 112.4, 48.7, and 18.3 months for stage I, II, III, and IV, respectively. Early stage (stage I), endometriosis, and optimal debulking were identified as favorable prognostic factors for RFS. Early stage and optimal debulking were also favorable prognostic factors for OS. Majority of patients with early stage received adjuvant chemotherapy. However, additional survival benefit was not found in terms of recurrence. Conclusion: Majority of patients had early stage and received postoperative chemotherapy regardless of stage. Early stage and optimal debulking were identified as favorable prognostic factors. In stage IA or IB, adding adjuvant chemotherapy did not show difference in survival. Further study focusing on OCCC is required.
Keywords
CarcinomaOvarian EpithelialAdenocarcinomaClear cellKoreaChemotherapyAdjuvant
URI
http://kumel.medlib.dsmc.or.kr/handle/2015.oak/42323
Appears in Collections:
1. Journal Papers (연구논문) > 1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
Keimyung Author(s)
김진영
Full Text
https://www.e-crt.org/journal/view.php?doi=10.4143/crt.2019.292
File in this Item
oak-2019-0299.pdf(542.75 kB)Download
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE